PHARMACYTE BIOTECH INC (PMCB)

Company Profile

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The firm is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. The Company’s product candidate is referred to as CypCaps. The company is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. The company is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The company is also developing therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.

Company Info

PHARMACYTE BIOTECH INC

3960 Howard Hughes Parkway, Suite 500

Las Vegas NEVADA

P: 19175952850

CEO: Kenneth L. Waggoner

Employees: 2

Website: https://pharmacyte.com/